Highlights from partner talks at EANO 2026
The KU Leuven team attended EANO 2026 in Rome and Chiara Caprioli and Frederik De Smet presented glioblastoma research and a patient-derived brain tumour model. Discover highlights from the conference.
Presenting research on radiotherapy resistance in paediatric glioma at SIOPE BTG 2026
At the SIOPE Brain Tumour Group Annual Meeting 2026, KU Leuven researcher Julie Morscio discussed how patient-derived tumour models can help investigate why diffuse midline glioma cells survive radiotherapy. Read her testimonial.
GLIOMATCH: Explained with Dr. Chiara Caprioli and Prof. Frederik De Smet
In this GLIOMATCH: Explained episode, Dr. Chiara Caprioli and Prof. Frederik De Smet from KU Leuven explain how new research has mapped the evolution of glioblastoma from diagnosis to recurrence, identified distinct tumour trajectories and established a framework that could support more personalised treatment decisions.
GLIOMATCH: Explained with Prof. Dr. Sandra Jacobs
In this GLIOMATCH: Explained episode, Prof. Dr. Sandra Jacobs introduces the paediatric clinical study, the participating centres and the challenges of working with archived samples from paediatric high-grade glioma patients.
GLIOMATCH marks World Brain Tumour Day at EU event on advancing brain cancer research
On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.
GLIOMATCH: Explained with Prof. Dr. Steven De Vleeschouwer
In this GLIOMATCH: Explained episode, Prof. Dr. Steven De Vleeschouwer introduces the prospective clinical trials, the participating centres and the immunotherapy strategies being investigated to better understand patient response in brain tumours.
GLIOMATCH 5th consortium meeting takes place in Barcelona
On 28–29 April 2026, the GLIOMATCH consortium gathered in Barcelona, Spain, for its fifth consortium meeting, hosted by project partner Sant Joan de Déu Barcelona Children’s Hospital and the Fundació de Recerca Sant Joan de Déu (FSJD).
Second annual meeting of the Understanding (tumour-host interactions) Cluster held in Warsaw
GLIOMATCH joined partners of the Understanding (tumour-host interactions) Cluster – an initiative of the EU’s Cancer Mission – in Warsaw in March 2026 to review scientific progress, strengthen collaboration and advance joint work on data management and policy-relevant research.
GLIOMATCH results contribute to new EIC-funded project GLIOBREAK
Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.
International Childhood Cancer Day 2026
On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.